Clinical Trial Search

Primary: Cmax — 15300; 14200; 11200 NG/ML — p=0.4847

Primary: Participants With Local Adverse Events (AEs) - Year One — 3; 1; 0; 0 Participants

Primary: Number of Clinical Malaria Episodes Per Year of Follow-up — 0.61; 0.68; 0.64; 0.59 Episodes per PYAR — p=0.8097

Primary: Haemoglobin Level — 88.3; 89.2; 88.4; 89.6 g/L — p=<0.05

Primary: Changes From Baseline in Actinic Keratosis - Lesion Base Count. — 1.15; 2.65; 1.15; 2.60 lesions — p=<0.001

Primary: Cure Rates of AQ-13 and Coartem for Uncomplicated Plasmodium Falciparum Malaria in Adult Malian Males. — 28; 31 Participants

Primary: Number of Participants With Local Adverse Events (AEs) — 7; 1; 0; 0 Participants

Primary: Changes in Haemoglobin Concentration From Day 3 Post Treatment of Malaria Episode to Day 90 in the Weekly Chloroquine and Placebo Arms — 93.4; 93.7 g/L

Primary: Change in Haemoglobin Compared to the Baseline — 0.18; 0.54 g/dl

Primary: Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the First Vaccination — 0; 5; 0; 12 Participants

Primary: Safety and Reactogenicity (SAEs and AEs) — 45; 53; 22; 37 Number of events

Primary: Number of Participants With Positive Sensitive Blood Smear (sBS) — 0; 0 Participants

Primary: SLICC Score — 62; 56; 46; 41 participants — p=0.72

Primary: Freedom From Seizure — 7 individuals

Primary: Number of Participants With Local Adverse Events (AEs) — 0; 1; 1; 1 Participants

Primary: Prophylactic Efficacy of 3 Different Doses of Atovaquone/Proguanil (Malarone@) Given 1 Week Before Infectious Sporozoite Challenge Using the P. Falciparum Human…

Primary: Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 — 15; 14; 15; 15 Participants

Primary: Malaria Incidence — 0.0176; 0.0183 Malaria cases per person-week

Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation of Study Treatment — 13; 6; 5; 3…

Primary: Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment — 0; 0 participants

Primary: Participants With Local Adverse Events (AEs) — 1; 0; 0; 2 Participants

Primary: 25-hydroxyvitamin D at Visit 7 — 36.7; 39.8 ng/mL

Primary: Hemoglobin (g/dL) — 10.90; 10.30 g/dL

Primary: Parasite Clearance Half-life — 1.733; 1.973 Hours — p=>0.05

Primary: Number of Participants With Local and Systemic Adverse Events in Year 1 — 2; 6; 4; 6 Participants

Primary: Histological Lesion Clearance — 61.5; 38.5 percentage of complete clearance — p=0.375

Primary: Number of Participants Who Experience a Serious Adverse Events (SAEs) 29 Days After the Last Vaccination — 1; 0; 0; 1 Participants

Primary: Number of Local and Systemic Adverse Events (AEs) to Assess the Safety of the Study Drug — 34; 24; 23; 16 Adverse Events

Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…

Primary: Infection Rate — 5; 6; 3; 0 Participants